Cargando…

Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies

SIMPLE SUMMARY: Non-small cell lung cancer is common and potentially lethal. Existing treatments that enable a person’s own immune system to attack their cancer significantly improve survival, but only for a minority of people. This difference between people likely depends on the types of cells, sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Simon, Ottensmeier, Christian H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571797/
https://www.ncbi.nlm.nih.gov/pubmed/37835491
http://dx.doi.org/10.3390/cancers15194797
_version_ 1785120085538504704
author Gray, Simon
Ottensmeier, Christian H.
author_facet Gray, Simon
Ottensmeier, Christian H.
author_sort Gray, Simon
collection PubMed
description SIMPLE SUMMARY: Non-small cell lung cancer is common and potentially lethal. Existing treatments that enable a person’s own immune system to attack their cancer significantly improve survival, but only for a minority of people. This difference between people likely depends on the types of cells, secreted molecules and other conditions present in and around the tumour. New technologies have recently allowed many cell types and molecules to be identified on the same tumour slide, whereas previously only a few cell markers could be used; this allows common and rare cell types to be reliably identified, and the relationships between different cells and cell types to be studied in far greater detail than before. These technologies may help to identify new cancer treatments to improve outcomes for patients. Here, we review studies which have used these new technologies in non-small cell lung cancer, and aim to summarise their findings. ABSTRACT: Non-small cell lung cancer (NSCLC) remains a cause of significant morbidity and mortality, despite significant advances made in its treatment using immune checkpoint inhibitors (ICIs) over the last decade; while a minority experience prolonged responses with ICIs, benefit is limited for most patients. The development of multiplexed antibody-based (MAB) spatial tissue imaging technologies has revolutionised analysis of the tumour microenvironment (TME), enabling identification of a wide range of cell types and subtypes, and analysis of the spatial relationships and interactions between them. Such study has the potential to translate into a greater understanding of treatment susceptibility and resistance, factors influencing prognosis and recurrence risk, and identification of novel therapeutic approaches and rational treatment combinations to improve patient outcomes in the clinic. Herein we review studies that have leveraged MAB technologies to deliver novel insights into the TME of NSCLC.
format Online
Article
Text
id pubmed-10571797
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105717972023-10-14 Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies Gray, Simon Ottensmeier, Christian H. Cancers (Basel) Review SIMPLE SUMMARY: Non-small cell lung cancer is common and potentially lethal. Existing treatments that enable a person’s own immune system to attack their cancer significantly improve survival, but only for a minority of people. This difference between people likely depends on the types of cells, secreted molecules and other conditions present in and around the tumour. New technologies have recently allowed many cell types and molecules to be identified on the same tumour slide, whereas previously only a few cell markers could be used; this allows common and rare cell types to be reliably identified, and the relationships between different cells and cell types to be studied in far greater detail than before. These technologies may help to identify new cancer treatments to improve outcomes for patients. Here, we review studies which have used these new technologies in non-small cell lung cancer, and aim to summarise their findings. ABSTRACT: Non-small cell lung cancer (NSCLC) remains a cause of significant morbidity and mortality, despite significant advances made in its treatment using immune checkpoint inhibitors (ICIs) over the last decade; while a minority experience prolonged responses with ICIs, benefit is limited for most patients. The development of multiplexed antibody-based (MAB) spatial tissue imaging technologies has revolutionised analysis of the tumour microenvironment (TME), enabling identification of a wide range of cell types and subtypes, and analysis of the spatial relationships and interactions between them. Such study has the potential to translate into a greater understanding of treatment susceptibility and resistance, factors influencing prognosis and recurrence risk, and identification of novel therapeutic approaches and rational treatment combinations to improve patient outcomes in the clinic. Herein we review studies that have leveraged MAB technologies to deliver novel insights into the TME of NSCLC. MDPI 2023-09-29 /pmc/articles/PMC10571797/ /pubmed/37835491 http://dx.doi.org/10.3390/cancers15194797 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gray, Simon
Ottensmeier, Christian H.
Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies
title Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies
title_full Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies
title_fullStr Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies
title_full_unstemmed Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies
title_short Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies
title_sort advancing understanding of non-small cell lung cancer with multiplexed antibody-based spatial imaging technologies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571797/
https://www.ncbi.nlm.nih.gov/pubmed/37835491
http://dx.doi.org/10.3390/cancers15194797
work_keys_str_mv AT graysimon advancingunderstandingofnonsmallcelllungcancerwithmultiplexedantibodybasedspatialimagingtechnologies
AT ottensmeierchristianh advancingunderstandingofnonsmallcelllungcancerwithmultiplexedantibodybasedspatialimagingtechnologies